VERAMYST SUMMARY
Fluticasone furoate, the active component of VERAMYST Nasal Spray, is a synthetic fluorinated corticosteroid having the chemical name (6α,11β,16α,17α)-6,9-difluoro-17-{[(fluoro-methyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate and the following chemical structure.
VERAMYST Nasal Spray is a corticosteroid indicated for treatment of symptoms of seasonal and perennial allergic rhinitis in adults and children ≥2 years. (1.1)
VERAMYST® (fluticasone furoate) Nasal Spray is indicated for the treatment of the symptoms of seasonal and perennial allergic rhinitis in patients aged 2 years and older.
|
|
NEWS HIGHLIGHTSMedia Articles Related to Veramyst (Fluticasone Nasal)
Hay Fever (Allergic Rhinitis)
Source: MedicineNet Allergic Cascade Specialty [2016.10.07]
Title: Hay Fever (Allergic Rhinitis)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 10/7/2016 12:00:00 AM
Published Studies Related to Veramyst (Fluticasone Nasal)
An integrated analysis of the efficacy of fluticasone furoate nasal spray versus
placebo on the nasal symptoms of perennial allergic rhinitis. [2013]
Intranasal corticosteroids are widely prescribed for the treatment of perennial
allergic rhinitis (PAR). The aim of this analysis was to determine whether the
beneficial effects of once-daily (q.d.) fluticasone furoate nasal spray (FFNS)
effectively improved individual nasal symptoms of PAR...
MP29-02 (a novel intranasal formulation of azelastine hydrochloride and
fluticasone propionate) in the treatment of seasonal allergic rhinitis: a
randomized, double-blind, placebo-controlled trial of efficacy and safety. [2012]
Many patients with allergic rhinitis (AR) have uncontrolled symptoms despite
available treatment options. This study was designed to evaluate the efficacy and
safety of MP29-02 (a novel intranasal formulation of fluticasone propionate [FP]
and azelastine [AZ] hydrochloride), compared with monotherapy with FP, AZ, and
placebo sprays for the treatment of seasonal allergic rhinitis (SAR)...
Effect of fluticasone furoate on interleukin 6 secretion from adenoid tissues in children with obstructive sleep apnea. [2011.06]
OBJECTIVE: To determine the effect of intranasal corticosteroid therapy on T-regulatory cells and other inflammatory cytokines in adenoid tissues in children with obstructive sleep apnea syndrome... CONCLUSIONS: In this study, we show reduction of IL-6, a proinflammatory cytokine, in adenoid tissue obtained from children with obstructive sleep apnea syndrome treated with fluticasone furoate nasal spray. This reduction could contribute to the clinical efficacy of this class of medications in the treatment of childhood obstructive sleep apnea syndrome.
Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis. [2011.04]
BACKGROUND: In clinical trials, only about 60% of subjects report an excellent response to intranasal steroids, suggesting a need to add therapies to intranasal steroids to provide additional efficacy. OBJECTIVE: To determine whether the combination of fluticasone furoate and oxymetazoline is more efficacious than either agent alone, and to determine whether rhinitis medicamentosa develops after treatment... CONCLUSION: The addition of oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis. The lack of development of rhinitis medicamentosa suggests the need for a large multicenter study to develop a once-a-day combination of an intranasal steroid and a long-acting topical decongestant. Copyright (c) 2011 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment
of perennial allergic rhinitis. [2011]
whether rhinitis medicamentosa develops after treatment... CONCLUSION: The addition of oxymetazoline adds to the effectiveness of
Clinical Trials Related to Veramyst (Fluticasone Nasal)
Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth [Recruiting]
Children with mild persistent asthma that have asthma symptoms once or twice a week and use
a daily controller, while children with mild intermittent asthma rarely have asthma symptoms
and do not use a daily controller. Inhaled corticosteroids are the standard treatment for
mild peristent asthma. The purpose of this study is to measure children rate of growth
while on different inhaled corticosteroids.
A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 Mcg Twice Daily In Symptomatic Patients With Asthma [Completed]
This purpose of this study is to show the superiority and long term safety and efficacy of
adding a long acting beta agonist (salmeterol) to constant dose of an inhaled corticosteroid
(fluticasone propionate) in symptomatic subjects with asthma. The 12-month assessment of
asthma control will provide key information on the efficacy and safety of the combination
therapy. The safety measure will be an assessment of adverse events
Sensitivity of Pharmacokinetics to Differences in Aerodynamic Particle Size Distribution [Recruiting]
When a drug company first develops a drug, the company has to show the Food and Drug
Administration (FDA) that the drug is safe and effective. If FDA concludes that the drug is
safe and effective, FDA approves the drug. The company can then sell the drug, which the
company does using "trade name." Only the drug company that developed the "trade name" drug
is allowed to sell it. However, other drug companies can create their own version of the
"trade name" drug, which usually happens after the patents for the "trade name" product run
out. These drugs, often called "generic drugs," potentially will be less expensive for the
patient. In order to sell generic drugs, drug companies must show that their generic
version is the same as the "trade name" drug in a number of ways. For example, they
generally have to show that their product is intended to be used to treat the same diseases
or conditions, that it has the same label, and that the product has the same active
ingredient as the "trade name" drug. The generic company also has to show that generic
product is "bioequivalent" to the trade name drug, meaning that the generic product gets to
the part of the body where the drug works at the same rate that the trade name drug does.
How to show how much drug gets to the part of the body where it works, and how fast, depends
on the type of product the drug is. The primary aim of this research study is to aid the
FDA in finding methods to ensure that the versions of generic drugs that are inhaled (for
example, drugs used to treat asthma) are bioequivalent to the trade name drug. As a part of
the research study, pharmacokinetic (PK) studies (studies measuring drug levels in the blood
over time after inhalation) will be done using three different versions of fluticasone
propionate (FP, a drug routinely used in asthmatic patients) administered using a dry powder
inhaler (DPI, an inhalation device that delivers the drug as a dry powder). The results
from this study will help FDA ensure that generic products are the same as the trade name
drugs.
Seretide Versus Flixotide In Asthmatic Children Not Controlled By Inhaled Corticosteroids [Completed]
This study will compare two treatment strategies (doubling the dose of inhaled steroids or
adding a long acting beta2 agonist to the inhaled steroid at the same dose) in children not
controlled by inhaled steroid alone at medium dose. The fixed combination SERETIDE 100/50
one inhalation twice daily will be compared to FLIXOTIDE 100 two inhalations twice daily.
A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149 [Completed]
To demonstrate the non-inferiority of QVA149 110/50 µg o. d. to fluticasone/salmeterol 500/50
µg b. i.d. in terms of trough Forced Expiratory Volume in one second (FEV1) (mean of 23 hours
15 min and 23 hours 45 min post QVA149 dose) following 26 weeks of treatment in patients
with moderate to severe COPD
Reports of Suspected Veramyst (Fluticasone Nasal) Side Effects
Drug Ineffective (22),
Epistaxis (22),
Product Quality Issue (16),
Headache (10),
Overdose (8),
Cough (8),
Nasal Discomfort (7),
Nasal Congestion (6),
Adverse Event (5),
Nasal Dryness (5), more >>
|
|
|
|
Page last updated: 2016-10-07
|
